The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation
Authors:
Open Access
- 15 April 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (4) , e14587
Abstract
INTRODUCTION: Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging.METHODS: To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts.RESULTS: CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more comparable than their original scales across various biomarkers.DISCUSSION: The versatility of CentiMarkers makes it a valuable tool for standardized biomarker comparison in AD research, enabling informed cross‐study comparisons and contributing to accelerated therapeutic development. Adoption of the CentiMarker scale could enhance biomarker reporting and advance our understanding of AD.Highlights: Comparing fluid biomarkers without appreciating their magnitude relative to the disease can be challenging. We propose a CentiMarker metric to standardize biomarker measures from normal (0) and nearly maximum abnormal AD (100) ranges. CentiMarkers make the treatment effect more comparable across various biomarkers than when using the original scales.Keywords
All Related Versions
Funding Information
- National Institute on Aging
- National Institutes of Health (U01 AG024904, U01AG042791‐S1)
- Alzheimer's Association
- Eli Lilly and Company
- Avid Radiopharmaceuticals
- GHR Foundation
- Alzheimer's Disease Neuroimaging Initiative
- U.S. Department of War (W81XWH‐12‐2‐0012)
- National Institute of Biomedical Imaging and Bioengineering
- Foundation for the National Institutes of Health (U01AG052564)
This publication has 18 references indexed in Scilit:
- CSF biomarkers for dementiaPractical Neurology, 2022
- Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer diseaseAlzheimer's & Dementia, 2021
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseNature Medicine, 2021
- A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s diseaseNature Medicine, 2020
- Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's diseaseAlzheimer's & Dementia, 2019
- Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onsetAlzheimer's & Dementia, 2019
- Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer diseaseNeurology, 2018
- CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisationClinica Chimica Acta, 2017
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PETAlzheimer's & Dementia, 2014
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012